ABOUND Data Explores Safety and Efficacy of ABRAXANE® for the Treatment of Patients with Lung Cancer

Celgene Igea Luca Dezzani

Dec 6, 2016

Celgene Corporation has announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in patients with advanced non-small cell lung cancer (NSCLC). Interim data presented from the ABOUND trials during the IASLC 17th World Conference on Lung Cancer (WCLC) reinforces the benefit of ABRAXANE/carboplatin doublet therapy in first-line NSCLC.

US FDA accepts first biologics license application for durvalumab of AstraZeneca for the treatment of patients with bladder cancer

astra

9 December 2016

AstraZeneca and its global biologics research and development arm, MedImmune, have announced that the US Food and Drug Administration (FDA) has accepted the first Biologics License Application (BLA) for durvalumab, a PD-L1 human monoclonal antibody (mAb). FDA has also granted priority review status with a Prescription Drug User Fee Act (PDUFA) set for the second quarter of 2017.

Positive Results Found in the Use of ABRAXANE® as First-Line Treatment of Metastatic Triple Negative Breast Cancer

Celgene Igea Luca Dezzani

13 December 2016

The results of Celgene’s randomized phase II tnAcity trial of ABRAXANE® for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) were presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) in December 6-10, 2016. The trial found that an investigational weekly combination regimen of ABRAXANE + carboplatin had significantly longer progression-free survival (PFS) (7.4 months) compared to weekly regimens of either ABRAXANE + gemcitabine (5.4 months) or of carboplatin + gemcitabine (6.0 months) as first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).

Johnson & Johnson Looks for the Right Deal

jnj

Dec 15, 2016

The auction process to acquire Pharmacyclics was too competitive, and Actelion Pharmaceuticals was too expensive for Johnson & Johnson. Is there any deal that will be just right for J&J? Officials from Johnson & Johnson announced that it had ended discussions with Actelion on a potential deal. Analysts say that J&J is flush with cash and needs to do a deal soon. Now, the question is, what is J&J looking for?

LinkedIn releases the List of the Top Voices in Healthcare for 2016

linkedin

Dec 15, 2016

LinkedIn has recently released the list of the 10 top voices 2016 in healthcare. Luca Dezzani, editor of Igeahub.com, has been included in this list. As the Global Medical Director at Novartis Oncology, Dr. Dezanni has been actively writing about clinical research, healthcaredrug and biotechnology industries, diagnostics and medical devices. His contributions also include suggestions regarding the best possible ways to deliver better patient care at the lowest cost. He also emphasized on the possibility of providing personalized treatment to the patients in order to ensure better treatment facilities.

Lonza Buys Capsugel in $5.5 Billion Health Care Deal

lonza-capsugel

Dec 15, 2016

Lonza has declared that it will buy private-equity backed U.S. capsule maker Capsugel in a $5.5 billion all-cash deal. This will push the Swiss biotech group further into the health care industry.

The Plan for Drug Price Cap Nullified by White House

white-house

Dec 16, 2016

The Obama administration has decided to quit on a plan to fight high drug prices that drew strong opposition from both parties and also from apparently all sectors of the healthcare industry. It was confirmed by a spokesperson for the agency regulating Medicare and Medicaid.

Lilly’s Baricitinib is Recommended by CHMP for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)

Lilly

Dec. 16, 2016

Eli Lilly and Company and Incyte Corporation have announced that the Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA) has issued a positive opinion recommending the approval of baricitinib – which if approved, would be marketed as Olumiant®. Baricitinib is recommended to be used for treating moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with methotrexate. This recommendation from CHMP is expected to be followed by the approval from the European Commission, who will make the decision on marketing authorization.

Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug

clovis-oncology

Dec 19, 2016

Clovis Oncology has got the approval from U.S. FDA for its PARP inhibitor rucaparib for treating women with advanced ovarian cancer, who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA). The brand name of the drug is Rubraca.

Allergan Signs $2.9 Billion Breast Cancer Deal

2000px-allergan_plc-svg

Dec 20, 2016

Allergan, a New Jersey based pharmaceutical company, is ending this year on a high note with yet another biotech purchase. It has announced that that it will acquire LifeCell from privately-held Acelity for $2.9 billion in cash. LifeCell focuses on breast reconstruction surgery devices and drugs and is expected to generate $450 million in 2016 revenue.

BMS and Calithera Announce Clinical Collaboration to Evaluate nivolumab in combination with CB-839 for Renal Cell Carcinoma

Bristol-Myers

December 21, 2016

Bristol-Myers Squibb Company and Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing new small molecule drugs directed against tumor metabolism and tumor immunology targets for treating cancer, have announced a clinical trial collaboration to evaluate the Opdivo of Bristol-Myers Squibb in combination with  CB-839 of Calithera in patients with clear cell renal cell carcinoma (ccRCC). CB-839 is an orally administered glutaminase inhibitor currently in Phase 1/2 clinical studies.

 

Roche’s emicizumab for the Treatment of haemophilia A meets primary endpoint in phase III study

Roche Igea Luca Dezzani

22 December 2016

Roche has announced that the primary endpoint has been met for the phase III HAVEN 1 study assessing emicizumab prophylaxis in people with haemophilia A and inhibitors to factor VIII. The study revealed a statistically significant reduction in the number of bleeds over time in people treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. All secondary endpoints were also met, including a statistically significant reduction in the number of bleeds over time with emicizumab prophylaxis treatment in an intra-patient comparison in people who had received prior bypassing agent prophylaxis treatment. Injection site reactions were the most common adverse events with emicizumab, as consistent with prior studies.

Biogen and Ionis Receive FDA Approval for spinal muscular atrophy drug Spinraza
December 23, 2016

biogen-ionis

FDA announced that it had provided an accelerated approval for Spinraza (nusinersen), the new drug from Biogen and Ionis, for treating rare cases of spinal muscular atrophy. It is estimated that the total sales of this drug would reach $3 billion by 2026. On this news, shares of Ionis climbed 10% and Biogen saw its stock shot up 2%. After a year of upheavals, both companies badly needed this win.

Abbott Set to Complete Acquisition of St. Jude Medical on January 4, 2017

abbott

Dec. 30, 2016

Abbott Laboratories has announced that it plans to close the acquisition of St. Jude Medical, Inc., on Wednesday, Jan. 4, 2017. The announcement follows receipt of all regulatory clearances required for closing.

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s